Biotron to present HIV trial data at IAS 2013
Biotron (ASX:BIT) has been chosen to present details of a phase IIa trial of antiviral candidate BIT225 at this year’s IAS Conference on HIV Pathogenesis, Treatment and Prevention.
The conference is this year being held in Malaysia from 28 June to 3 July. Biotron will present at the conference proper, as well as the preceding ‘Towards an HIV Cure’ symposium.
“This is an important opportunity to highlight and expand on the encouraging results we have achieved to date with BIT225 in HIV-infected patients,” Biotron managing director Dr Michelle Miller said.
The phase IIa trial was conducted in Bangkok and involved 21 HIV patients with high levels of virus, good CD4+ T cell counts and no prior exposure to antiretroviral drugs.
Preliminary results announced in March support BIT225’s potential to target HIV reservoir precursor cells.
The company is also trialling BIT225 in hepatitis C (HCV) and in patients co-infected with HIV and HVC.
Biotron shares were trading unchanged at $0.10 as of around 1 pm on Friday.
Scientists find new driver of ovarian cancer spread
A cell surface receptor known as F2R could serve as both a diagnostic marker for ovarian cancer...
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
